Stock Events

Stock Events

Vistagen Therapeutics 

$0.2520
86
+$0.00+0.8% 10:04 Today

Statistics

Day High
0.2464
Day Low
0.2464
52W High
5.14
52W Low
0.2
Volume
3,888
Avg. Volume
-
Mkt Cap
10.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-0.54
-0.46
-0.38
-0.3
Expected EPS
-0.375
Actual EPS
N/A

Financials

-5,491.33%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.27MRevenue
-69.69MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTGN. It's not an investment recommendation.
Apple
12
AAPL
Microsoft
12
MSFT
Realty Income
12
O
AMD
12
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops treatments for mental health disorders, overlapping with VistaGen's focus.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong portfolio in psychiatric and neurological disorders, making it a direct competitor in the mental health treatment market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad range of products for neurological and psychiatric conditions, competing with VistaGen in the mental health space.
Merck
MRK
Mkt Cap366B
Merck & Co. invests in research and development for central nervous system disorders, including depression and anxiety, areas VistaGen is also targeting.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes focuses on central nervous system disorders, including treatments for depression, directly competing with VistaGen's therapeutic focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a portfolio that includes CNS treatments, making it a competitor in the mental health pharmaceutical market.
Novartis
NVS
Mkt Cap292.35B
Novartis has a diversified portfolio that includes treatments for neurological conditions, positioning it as a competitor in the broader CNS therapeutic area.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, with its acquisition of Allergan, has expanded its CNS portfolio, including treatments for mental health disorders, competing with VistaGen.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb has a strong focus on neuroscience, including treatments for psychiatric disorders, making it a competitor in the mental health field.

About

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Show more...
CEO
Shawn K. Singh
Employees
41
Country
United States
ISIN
US92840H4002

Listings

XNAS
US
VTGN
BOATS
BOATS
VTGN.BOATS
MX
MX
VTGN.MX

0 Comments

Share your thoughts

FAQ

What is Vistagen Therapeutics stock price today?▼
The current price of VTGN is $0.25 USD — it has increased by +0.8% in the past 24 hours. Watch Vistagen Therapeutics stock price performance more closely on the chart.
What is Vistagen Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Vistagen Therapeutics stocks are traded under the ticker VTGN.
Is Vistagen Therapeutics stock price growing?▼
VTGN stock has risen by +0% compared to the previous week, the month change is a -16.67% fall, over the last year Vistagen Therapeutics has showed a -93.09% decrease.
What is Vistagen Therapeutics market cap?▼
Today Vistagen Therapeutics has the market capitalization of 10.93M
When is the next Vistagen Therapeutics earnings date?▼
Vistagen Therapeutics is going to release the next earnings report on November 05, 2026.
What were Vistagen Therapeutics earnings last quarter?▼
VTGN earnings for the last quarter are -0.3 USD per share, whereas the estimation was -0.37 USD resulting in a +17.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vistagen Therapeutics revenue for the last year?▼
Vistagen Therapeutics revenue for the last year amounts to 1.27M USD.
What is Vistagen Therapeutics net income for the last year?▼
VTGN net income for the last year is -69.69M USD.
How many employees does Vistagen Therapeutics have?▼
As of September 04, 2026, the company has 41 employees.
In which sector is Vistagen Therapeutics located?▼
Vistagen Therapeutics operates in the Health & Wellness sector.
When did Vistagen Therapeutics complete a stock split?▼
The last stock split for Vistagen Therapeutics was on June 07, 2023 with a ratio of 1:30.
Where is Vistagen Therapeutics headquartered?▼
Vistagen Therapeutics is headquartered in SOUTH SAN FRANCISCO, United States.